Neuphoria Therapeutics Inc. (NEUP)

Market Cap	11.10M
Revenue (ttm)	15.65M
Net Income (ttm)	-369,632
Shares Out	2.36M
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	883,468
Open	4.760
Previous Close	4.530
Day's Range	4.645 - 5.090
52-Week Range	2.900 - 126.000
Beta	n/a
Analysts	Strong Buy
Price Target	28.00 (+494.48%)
Earnings Date	Nov 15, 2025

About NEUP

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: NEUP
• Website: https://www.neuphoriatx.com

Analyst Summary

According to 2 analysts, the average rating for NEUP stock is "Strong Buy." The 12-month stock price target is $28.0, which is an increase of 494.48% from the latest price.

Price Target

$28.0

(494.48% upside)

Analyst Consensus: Strong Buy